Novel Role for Inhibitor of Differentiation 2 in the Genesis of Angiotensin II-Induced Hypertension

Circulation

Volumn 117, Issue 20, 2008, Pages 2645-2656

  Gratze, Petra ^a   Dechend, Ralf ^a   Stocker, Carolin ^a   Park, Joon Keun ^a   Feldt, Sandra ^a   Shagdarsuren, Erdenechimeg ^e   Wellner, Maren ^a   Gueler, Faikah ^c   Rong, Song ^c   Gross, Volkmar ^b   Obst, Michael ^b   Plehm, Ralph ^b   Alenina, Natalia ^b   Zenclussen, Ana ^a   Titze, Jens ^g   Small, Kersten ^h   Yokota, Yoshifumi ^f   Zenke, Martin ^d   Luft, Friedrich C ^a,b   Muller, Dominik N ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d RWTH AACHEN UNIVERSITY   (Germany)

^e RWTH AACHEN UNIVERSITY   (Germany)

^f UNIVERSITY OF FUKUI   (Japan)

^g UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^h MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Angiotensin; Hypertension; Immune system; Kidney; Vasoconstriction

Indexed keywords

ANGIOTENSIN II; BONE MORPHOGENETIC PROTEIN 4; CD8ALPHA ANTIGEN; COLLAGEN TYPE 1; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 2A; INHIBITOR OF DIFFERENTIATION 2; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; BONE MARROW TRANSPLANTATION; CD8+ T LYMPHOCYTE; CELL AGING; CELL PROTECTION; CONTROLLED STUDY; DENDRITIC CELL; DISEASE COURSE; GENE DELETION; HORMONE SYNTHESIS; HYPERTENSION; KIDNEY GRAFT; KIDNEY INJURY; LANGERHANS CELL; LYMPHOCYTE COUNT; MALE; MEMORY T LYMPHOCYTE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TRANSGENIC MOUSE; VASCULAR SMOOTH MUSCLE; ANIMAL; BLOOD CELL; CHEMICALLY INDUCED DISORDER; CYTOLOGY; IMMUNE SYSTEM; IMMUNOLOGY; KIDNEY TRANSPLANTATION; MOUSE MUTANT; PHYSIOLOGY;

ANGIOTENSIN II; ANIMALS; BLOOD CELLS; BONE MARROW TRANSPLANTATION; HYPERTENSION; IMMUNE SYSTEM; INHIBITOR OF DIFFERENTIATION PROTEIN 2; KIDNEY TRANSPLANTATION; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC;

EID: 47649125169     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.107.760116     Document Type: Article

References (44)

1. Ong KL, Cheung BM, Man YB, Lau CP, Lam KS. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension. 2007;49:69-75.
2. Crowley SD, Gurley SB, Oliverio MI, Pazmino AK, Griffiths R, Flannery PJ, Spurney RF, Kim HS, Smithies O, Le TH, Coffman TM. Distinct roles for the kidney and systemic tissues in blood pressure regulation by the renin-angiotensin system. J Clin Invest. 2005;115:1092-1099.
3. Mehta PK, Griendling KK. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol. 2007;292:C82-C97.
4. Navar GL, Prieto-Carrasquero MC, Kobori H. Molecular aspects of the renal renin-angiotensin system. In: Re R, DiPette D, Schiffrin E, Sowers JR, eds. Molecular Mechanisms in Human Hypertension. London, UK: Taylor and Francis Group; 2006:3-14.
5. Muller DN, Heissmeyer V, Dechend R, Hampich F, Park JK, Fiebeler A, Shagdarsuren E, Theuer J, Elger M, Pilz B, Breu V, Schroer K, Ganten D, Dietz R, Haller H, Scheidereit C, Luft FC. Aspirin inhibits NF-kappaB and protects from angiotensin II-induced organ damage. FASEB J. 2001; 15:1822-1824.
6. Ruiz-Ortega M, Lorenzo O, Ruperez M, Blanco J, Egido J. Systemic infusion of angiotensin II into normal rats activates nuclear factor-kappaB and AP-1 in the kidney: role of AT(1) and AT(2) receptors. Am J Pathol. 2001;158:1743-1756.
7. Muller DN, Shagdarsuren E, Park JK, Dechend R, Mervaala E, Hampich F, Fiebeler A, Ju X, Finckenberg P, Theuer J, Viedt C, Kreuzer J, Heidecke H, Haller H, Zenke M, Luft FC. Immunosuppressive treatment protects against angiotensin II-induced renal damage. Am J Pathol. 2002; 161:1679-1693.
8. Shagdarsuren E, Wellner M, Braesen JH, Park JK, Fiebeler A, Henke N, Dechend R, Gratze P, Luft FC, Muller DN. Complement activation in angiotensin II-induced organ damage. Circ Res. 2005;97:716-724.
9. Benezra R, Rafii S, Lyden D. The Id proteins and angiogenesis. Oncogene. 2001;20:8334-8341.
10. Ruzinova MB, Benezra R. Id proteins in development, cell cycle and cancer. Trends Cell Biol. 2003;13:410-418.
11. Moskowitz IP, Kim JB, Moore ML, Wolf CM, Peterson MA, Shendure J, Nobrega MA, Yokota Y, Berul C, Izumo S, Seidman JG, Seidman CE. A molecular pathway including Id2, Tbx5, and Nkx2-5 required for cardiac conduction system development. Cell. 2007;129:1365-1376.
12. Kumar MS, Hendrix JA, Johnson AD, Owens GK. Smooth muscle alpha-actin gene requires two E-boxes for proper expression in vivo and is a target of class I basic helix-loop-helix proteins. Circ Res. 2003;92: 840-847.
13. Matsumura ME, Lobe DR, McNamara CA. Contribution of the helixloop- helix factor Id2 to regulation of vascular smooth muscle cell proliferation. J Biol Chem. 2002;277:7293-7297.
14. Cannarile MA, Lind NA, Rivera R, Sheridan AD, Camfield KA, Wu BB, Cheung KP, Ding Z, Goldrath AW. Transcriptional regulator Id2 mediates CD8- T cell immunity. Nat Immunol. 2006;7:1317-1325.
15. Hacker C, Kirsch RD, Ju XS, Hieronymus T, Gust TC, Kuhl C, Jorgas T, Kurz SM, Rose-John S, Yokota Y, Zenke M. Transcriptional profiling identifies Id2 function in dendritic cell development. Nat Immunol. 2003; 4:380-386.
16. Kusunoki T, Sugai M, Katakai T, Omatsu Y, Iyoda T, Inaba K, Nakahata T, Shimizu A, Yokota Y. TH2 dominance and defective development of a CD8- dendritic cell subset in Id2-deficient mice. J Allergy Clin Immunol. 2003;111:136-142.
17. Yokota Y, Mansouri A, Mori S, Sugawara S, Adachi S, Nishikawa S, Gruss P. Development of peripheral lymphoid organs and natural killer cells depends on the helix-loop-helix inhibitor Id2. Nature. 1999;397: 702-706.
18. Ziegler E, Gueler F, Rong S, Mengel M, Witzke O, Kribben A, Haller H, Kunzendorf U, Krautwald S. CCL19-IgG prevents allograft rejection by impairment of immune cell trafficking. J Am Soc Nephrol. 2006;17: 2521-2532.
19. Kang N, Walther T, Tian XL, Bohlender J, Fukamizu A, Ganten D, Bader M. Reduced hypertension-induced end-organ damage in mice lacking cardiac and renal angiotensinogen synthesis. J Mol Med. 2002;80: 359-366.
20. Gross V, Milia AF, Plehm R, Inagami T, Luft FC. Long-term blood pressure telemetry in AT2 receptor-disrupted mice. J Hypertens. 2000; 18:955-961.
21. Haller H, Quass P, Lindschau C, Luft FC, Distler A. Platelet-derived growth factor and angiotensin II induce different spatial distribution of protein kinase C-alpha and-beta in vascular smooth muscle cells. Hypertension. 1994;23:848-852.
22. Crowley SD, Gurley SB, Herrera MJ, Ruiz P, Griffiths R, Kumar AP, Kim HS, Smithies O, Le TH, Coffman TM. Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney. Proc Natl Acad Sci U S A. 2006;103:17985-17990.
23. Aoki Y, Mori S, Kitajima K, Yokoyama O, Kanamaru H, Okada K, Yokota Y. Id2 haploinsufficiency in mice leads to congenital hydronephrosis resembling that in humans. Genes Cells. 2004;9:1287-1296.
24. Perk J, Iavarone A, Benezra R. Id family of helix-loop-helix proteins in cancer. Nat Rev Cancer. 2005;5:603- 614.
25. Zhu X, Lin Y, Zhang J, Fu M, Mao Z, Chen YE. Thiazolidinediones, a class of anti-diabetic drugs, inhibit Id2 expression through a PPARgamma-independent pathway in human aortic smooth muscle cells. Cell Mol Life Sci. 2003;60:212-218.
26. Law RE, Goetze S, Xi XP, Jackson S, Kawano Y, Demer L, Fishbein MC, Meehan WP, Hsueh WA. Expression and function of PPARgamma in rat and human vascular smooth muscle cells. Circulation. 2000;101: 1311-1318.
27. Buchanan TA, Meehan WP, Jeng YY, Yang D, Chan TM, Nadler JL, Scott S, Rude RK, Hsueh WA. Blood pressure lowering by pioglitazone: evidence for a direct vascular effect. J Clin Invest. 1995;96:354-360.
28. Ryan MJ, Didion SP, Mathur S, Faraci FM, Sigmund CD. PPAR(gamma) agonist rosiglitazone improves vascular function and lowers blood pressure in hypertensive transgenic mice. Hypertension. 2004;43: 661-666.
29. Sarafidis PA, Lasaridis AN. Actions of peroxisome proliferator-activated receptors-gamma agonists explaining a possible blood pressure-lowering effect. Am J Hypertens. 2006;19:646-653.
30. Tordjman KM, Semenkovich CF, Coleman T, Yudovich R, Bak S, Osher E, Vechoropoulos M, Stern N. Absence of peroxisome proliferator-activated receptor-alpha abolishes hypertension and attenuates atherosclerosis in the Tsukuba hypertensive mouse. Hypertension. 2007;50:945-951.
31. Herrera J, Ferrebuz A, Macgregor EG, Rodriguez-Iturbe B. Mycophenolate mofetil treatment improves hypertension in patients with psoriasis and rheumatoid arthritis. J Am Soc Nephrol. 2006;17(suppl 3):S218-S225.
32. Tian N, Gu JW, Jordan S, Rose RA, Hughson MD, Manning RD Jr. Immune suppression prevents renal damage and dysfunction and reduces arterial pressure in salt-sensitive hypertension. Am J Physiol Heart Circ Physiol. 2007;292:H1018-H1025.
33. Nataraj C, Oliverio MI, Mannon RB, Mannon PJ, Audoly LP, Amuchastegui CS, Ruiz P, Smithies O, Coffman TM. Angiotensin II regulates cellular immune responses through a calcineurin-dependent pathway. J Clin Invest. 1999;104:1693-1701.
34. Ruiz-Ortega M, Esteban V, Ruperez M, Sanchez-Lopez E, Rodriguez-Vita J, Carvajal G, Egido J. Renal and vascular hypertensioninduced inflammation: role of angiotensin II. Curr Opin Nephrol Hypertens. 2006;15:159-166.
35. Suzuki Y, Gomez-Guerrero C, Shirato I, Lopez-Franco O, Hernandez- Vargas P, Sanjuan G, Ruiz-Ortega M, Sugaya T, Okumura K, Tomino Y, Ra C, Egido J. Susceptibility to T cell-mediated injury in immune complex disease is linked to local activation of renin-angiotensin system: the role of NF-AT pathway. J Immunol. 2002;169:4136-4146.
36. Jurewicz M, McDermott DH, Sechler JM, Tinckam K, Takakura A, Carpenter CB, Milford E, Abdi R. Human T and natural killer cells possess a functional renin-angiotensin system: further mechanisms of angiotensin II-induced inflammation. J Am Soc Nephrol. 2007;18: 1093-1102.
37. Whitman SC, Rateri DL, Szilvassy SJ, Yokoyama W, Daugherty A. Depletion of natural killer cell function decreases atherosclerosis in lowdensity lipoprotein receptor null mice. Arterioscler Thromb Vasc Biol. 2004;24:1049-1054.
38. Ohtsuka S, Yamazaki A, Oyake Y, Yamaguchi I. Amlodipine improves vascular function in patients with moderate to severe hypertension. J Cardiovasc Pharmacol. 2003;42:296-303.
39. Schiffrin EL. Effects of antihypertensive drugs on vascular remodeling: do they predict outcome in response to antihypertensive therapy? Curr Opin Nephrol Hypertens. 2001;10:617- 624.
40. Gizard F, Amant C, Barbier O, Bellosta S, Robillard R, Percevault F, Sevestre H, Krimpenfort P, Corsini A, Rochette J, Glineur C, Fruchart JC, Torpier G, Staels B. PPAR alpha inhibits vascular smooth muscle cellproliferation underlying intimal hyperplasia by inducing the tumor suppressor p16INK4a. J Clin Invest. 2005;115:3228-3238.
41. Buckley S, Shi W, Driscoll B, Ferrario A, Anderson K, Warburton D. BMP4 signaling induces senescence and modulates the oncogenic phenotype of A549 lung adenocarcinoma cells. Am J Physiol Lung Cell Mol Physiol. 2004;286:L81-L86.
42. Gorenne I, Kavurma M, Scott S, Bennett M. Vascular smooth muscle cell senescence in atherosclerosis. Cardiovasc Res. 2006;72:9-17.
43. Matthews C, Gorenne I, Scott S, Figg N, Kirkpatrick P, Ritchie A, Goddard M, Bennett M. Vascular smooth muscle cells undergo telomere-based senescence in human atherosclerosis: effects of telomerase and oxidative stress. Circ Res. 2006;99:156-164.
44. Guzik TJ, Hoch NE, Brown KA, McCann LA, Rahman A, Dikalov S, Goronzy J, Weyand C, Harrison DG. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J Exp Med. 2007;204:2449-2460.